Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
IBUPROFEN SODIUM vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.
Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.
Mild to moderate pain,Primary dysmenorrhea,Osteoarthritis,Rheumatoid arthritis,Fever reduction (FDA-approved OTC use),Migraine (OTC and prescription formulations)
Treatment of acute attacks of vivax malaria due to Plasmodium vivax,Radical cure of vivax malaria (elimination of hypnozoites),Suppression of malaria (prophylaxis) in areas with chloroquine-sensitive P. vivax
200-400 mg orally every 4-6 hours, maximum 1200 mg/day; for OTC use, 200-400 mg every 6-8 hours as needed, maximum 1200 mg/day.
Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.
2.0-2.5 hours (terminal); no prolongation in mild hepatic impairment; increased in renal failure.
Chloroquine: 40-60 days (terminal); Primaquine: 6-8 hours (terminal). Clinical context: chloroquine accumulates extensively, requiring prolonged monitoring for toxicity; primaquine, shorter half-life, once-daily dosing.
Primarily hepatic via CYP2C9; major metabolites are hydroxylated and carboxylated derivatives, with subsequent glucuronidation.
Chloroquine: hepatic metabolism via CYP2C8 and CYP3A4; primaquine: hepatic metabolism via CYP2D6 and other enzymes.
Renal: 90% as metabolites and conjugates, <1% unchanged; biliary/fecal: minor.
Renal: 70% (chloroquine as unchanged drug and metabolites), 20% (primaquine as metabolites); Fecal: ~10% (chloroquine); Biliary: minor for both.
99% bound to albumin.
Chloroquine: 50-65% bound to albumin; Primaquine: ~20% bound to albumin.
0.15-0.3 L/kg; distribution limited by high protein binding.
Chloroquine: Vd 100-200 L/kg (extensive tissue distribution); Primaquine: Vd 3-5 L/kg (moderate distribution). Clinical meaning: large Vd of chloroquine indicates deep tissue compartments with slow release.
Oral: 80-100% (rapid absorption); Topical: negligible systemic bioavailability (<5%).
Both: Oral bioavailability ~80-90% for chloroquine; ~90% for primaquine. No parenteral form for this combination.
GFR 30-90 m L/min: no adjustment needed. GFR <30 m L/min: avoid use; if necessary, reduce dose and extend interval (e.g., 200-400 mg every 8-12 hours). Not recommended in severe renal impairment (GFR <15 m L/min).
For chloroquine: GFR 10-50: 50% dose; GFR <10: 25% dose. For primaquine: No adjustment required, but monitor for hemolysis in GFR <10 due to accumulation.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (maximum 600 mg/day). Child-Pugh C: avoid use.
For chloroquine: Child-Pugh A/B: no adjustment; Child-Pugh C: reduce dose by 50% or avoid. For primaquine: Child-Pugh A/B: no data, use with caution; Child-Pugh C: contraindicated due to risk of hemolysis in glucose-6-phosphate dehydrogenase (G6PD) deficiency and impaired clearance.
Infants and children (≥6 months): 5-10 mg/kg per dose orally every 6-8 hours, maximum 40 mg/kg/day. For fever or pain, 5 mg/kg if temperature <102.5°F, 10 mg/kg if ≥102.5°F.
Chloroquine: 10 mg base/kg orally once daily for 2 days, then 5 mg base/kg once daily (max 300 mg base/day) for 2 weeks. Primaquine: 0.5 mg base/kg orally once daily for 14 days (max 30 mg base/day). Ensure G6PD screening before use.
Initiate at lowest effective dose (200 mg) and titrate slowly; maximum 1200 mg/day. Monitor renal function, GI bleeding risk, and drug interactions (e.g., ACE inhibitors, diuretics). Avoid chronic use if possible.
Use lower end of adult dose for chloroquine due to reduced renal function; adjust according to Cr Cl. For primaquine, monitor for G6PD deficiency and hemolysis; dose as per adult. Consider increased risk of QT prolongation with chloroquine.
None formally required for ibuprofen sodium, but NSAIDs carry increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke (especially with prolonged use or in patients with cardiovascular risk factors). NSAIDs also increase risk of serious GI adverse events including bleeding, ulceration, and perforation.
Primaquine may cause hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Test for G6PD deficiency before starting therapy.
Cardiovascular risk: increased risk of thrombotic events, MI, stroke; avoid in setting of CABG surgery.,GI risk: increased risk of bleeding, ulceration, perforation; caution in patients with history of peptic ulcer disease or GI bleeding.,Renal effects: may cause renal impairment, especially in elderly, volume-depleted, or those with pre-existing renal disease.,Anaphylactoid reactions: can occur in patients without prior exposure; cross-sensitivity with aspirin.,Hepatic effects: rare severe hepatic reactions; monitor liver function.,Hypertension: can worsen blood pressure control; monitor.,Asthma: may precipitate bronchospasm in aspirin-sensitive patients.
Hemolytic anemia (especially G6PD deficiency), bone marrow suppression, prolonged QT interval, visual disturbances (retinopathy with chloroquine), methemoglobinemia, and severe hypersensitivity reactions.
Hypersensitivity to ibuprofen or any NSAID,History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs,Active peptic ulcer disease or GI bleeding,Severe renal impairment (Cr Cl <30 m L/min),Severe hepatic impairment,Perioperative pain in the setting of coronary artery bypass graft (CABG) surgery,Late pregnancy (third trimester) due to risk of premature closure of ductus arteriosus
G6PD deficiency (primaquine), known hypersensitivity to chloroquine or primaquine, porphyria, concurrent use of drugs with known hemolytic potential, pregnancy (based on risk-benefit), and severe liver or kidney disease.
Avoid alcohol as it increases risk of GI bleeding. High-fat meals may slightly delay absorption but not clinically significant. St. John's Wort may reduce ibuprofen levels. No specific food restrictions.
No clinically significant food interactions reported. However, antacids containing magnesium or aluminum can reduce chloroquine absorption; separate administration by at least 4 hours. Grapefruit juice may increase chloroquine levels via CYP3A4 inhibition; avoid concurrent use.
First trimester: Avoid; associated with increased risk of cardiac defects and gastroschisis. Second trimester: Use with caution; limited evidence of structural anomalies. Third trimester: Contraindicated; risks include premature ductus arteriosus closure, oligohydramnios, and necrotizing enterocolitis.
In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuses. Second and third trimesters: chloroquine is safe, but primaquine should be avoided as fetal G6PD status is unknown.
Excreted into breast milk in low amounts (M/P ratio approximately 0.01-0.02). Considered compatible with breastfeeding due to low infant dose, but avoid if infant has thrombocytopenia or bleeding diathesis.
Chloroquine is excreted into breast milk in low concentrations; M/P ratio is approximately 0.5-0.6. Primaquine is excreted in breast milk; M/P ratio not well established. Breastfeeding is generally considered safe if infant is G6PD normal, but caution is advised due to potential for hemolysis in G6PD-deficient infants.
No specific dose adjustment required for pharmacokinetic changes in pregnancy; however, use lowest effective dose and shortest duration. Avoid in third trimester due to fetal risks. Increased renal clearance in pregnancy may reduce efficacy, but no dosing recommendations exist.
Chloroquine: No dose adjustment required; pharmacokinetics are not significantly altered. Primaquine: Contraindicated in pregnancy due to risk of hemolytic anemia in the fetus; no dose adjustment is applicable as it is not recommended.
Ibuprofen sodium is more rapidly absorbed than ibuprofen acid, leading to faster onset of analgesia (within 30 minutes). Use with caution in patients with cardiovascular disease, renal impairment, or history of GI bleeding. Avoid in late pregnancy (risk of premature ductus arteriosus closure). Monitor renal function in elderly and volume-depleted patients.
Combination of chloroquine and primaquine is used for radical cure of P. vivax and P. ovale malaria. Chloroquine is effective against blood-stage parasites; primaquine eradicates hypnozoites in the liver. Screen for G6PD deficiency before initiating primaquine to prevent hemolytic anemia. Concurrent use with hematotoxic drugs (e.g., dapsone) increases hemolysis risk. Contraindicated in G6PD-deficient patients, pregnancy, and breastfeeding unless no alternative. Monitor for QT prolongation, especially with electrolyte abnormalities or concurrent QT-prolonging agents.
Take with food or milk to reduce stomach upset.,Do not exceed recommended dose (1200 mg/day OTC) or duration (10 days for pain).,Avoid alcohol while taking ibuprofen to prevent GI irritation.,Stop and seek medical attention if signs of GI bleeding (black stools, vomit with blood) occur.,Consult doctor before use if you have high blood pressure, heart disease, kidney disease, or stomach ulcers.,Do not take with other NSAIDs or aspirin without physician approval.
Take with food or milk to reduce gastrointestinal upset.,Complete full course regardless of symptom resolution to prevent relapse.,Avoid alcohol during treatment due to risk of disulfiram-like reaction.,Report signs of hemolysis: dark urine, jaundice, pallor, fatigue (especially if G6PD deficient).,Do not take antacids containing magnesium or aluminum within 4 hours of chloroquine as they reduce absorption.,Seek medical attention for visual disturbances, QT prolongation symptoms (palpitations, syncope), or severe GI distress.,Use effective contraception during and for 1 month after treatment due to potential fetal harm from primaquine.
"Concomitant use of Ibuprofen (a nonsteroidal anti-inflammatory drug, NSAID) and Methylprednisolone (a systemic corticosteroid) synergistically increases the risk of gastrointestinal (GI) ulceration, bleeding, and perforation due to additive inhibition of prostaglandin synthesis and mucosal protection. Additionally, Ibuprofen may potentiate the immunosuppressive effects of Methylprednisolone, elevating infection risk. This interaction can lead to serious clinical outcomes, including acute GI hemorrhage, perforation, and impaired wound healing."
"The combination of olopatadine, an antihistamine with sedative properties, and ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), may result in additive central nervous system (CNS) depression, leading to increased sedation, dizziness, and impaired psychomotor function. Ibuprofen can inhibit the metabolism of olopatadine via competition for hepatic CYP450 enzymes, potentially elevating olopatadine plasma concentrations and prolonging its systemic effects. Clinically, patients may experience exacerbated drowsiness, reduced alertness, and increased risk of falls or accidents, especially in the elderly or those with compromised hepatic function."
"Ibuprofen, a nonsteroidal anti-inflammatory drug (NSAID), can decrease the metabolism of pioglitazone, a thiazolidinedione antidiabetic agent, by inhibiting cytochrome P450 2C8 (CYP2C8) enzyme activity. This inhibition elevates plasma concentrations of pioglitazone, potentially enhancing its hypoglycemic effects and increasing the risk of adverse reactions such as edema, weight gain, and heart failure exacerbation. Clinically, concomitant use may lead to improved glycemic control but also raises concerns for dose-dependent toxicities, necessitating careful monitoring and possible dose adjustment of pioglitazone."
"Alimemazine, a phenothiazine derivative with antihistaminergic and anticholinergic properties, may inhibit the metabolism of Primaquine, an antimalarial agent primarily metabolized by cytochrome P450 enzymes including CYP2D6 and CYP3A4. This interaction can lead to increased plasma concentrations of Primaquine, heightening the risk of dose-dependent adverse effects such as hemolytic anemia in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency and methemoglobinemia. Clinically, patients may present with signs of oxidant stress, including hemoglobinuria and jaundice."
"Eliglustat, a CYP2D6 substrate and inhibitor, can increase the systemic exposure of primaquine, which is primarily metabolized by CYP2D6. This elevation in primaquine concentration may potentiate its QTc-prolonging effects, leading to an increased risk of torsades de pointes and other ventricular arrhythmias. Caution is advised, especially in patients with pre-existing cardiac conditions or electrolyte abnormalities."
"Primaquine, an antimalarial agent, can inhibit the cardiac potassium channel encoded by the hERG gene, leading to prolongation of the QTc interval. Ivabradine, a funny current (If) inhibitor used for chronic heart failure, also possesses a mild QTc-prolonging effect. Concomitant use increases the risk of excessive QTc prolongation, which may precipitate torsade de pointes and other ventricular arrhythmias, particularly in patients with underlying risk factors such as electrolyte disturbances or bradycardia."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about IBUPROFEN SODIUM vs ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE, answered by our medical review team.
IBUPROFEN SODIUM is a NSAID that works by Non-selective inhibitor of cyclooxygenase (COX-1 and COX-2), decreasing prostaglandin synthesis, resulting in anti-inflammatory, analgesic, and antipyretic effects.. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is a Antimalarial that works by Chloroquine and primaquine: Chloroquine inhibits heme polymerase in malaria parasites, preventing conversion of toxic heme to hemozoin; primaquine disrupts mitochondrial function and generates reactive oxygen species, targeting hypnozoites and gametocytes.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between IBUPROFEN SODIUM and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of IBUPROFEN SODIUM is: 200-400 mg orally every 4-6 hours, maximum 1200 mg/day; for OTC use, 200-400 mg every 6-8 hours as needed, maximum 1200 mg/day.. The standard adult dose of ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is: Chloroquine phosphate 600 mg base (1 g salt) orally once daily for 2 days, then 300 mg base (500 mg salt) once daily for at least 2 weeks; plus primaquine phosphate 30 mg base orally once daily for 14 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between IBUPROFEN SODIUM and ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. IBUPROFEN SODIUM is classified as Category D/X. First trimester: Avoid; associated with increased risk of cardiac defects and gastroschisis. Second trimester: Use with caution; limited evidence of structural anomalies. Third tri. ARALEN PHOSPHATE W/ PRIMAQUINE PHOSPHATE is classified as Category D/X. In first trimester, chloroquine is generally considered low risk for major malformations, but primaquine is contraindicated due to risk of hemolytic anemia in G6PD-deficient fetuse. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.